Cole and Jaenisch dig into AI poisoning in pharma manufacturing, how it hides in plain sight, and who should be accountable for catching it.
|Articles|October 2, 2009
- Pharmaceutical Technology-10-02-2009
- Volume 33
- Issue 10
Pharmaceutical Technology, October 2009 Issue (PDF)
Getting the Truth Out of Dissolution Testing
Advertisement
Articles in this issue
about 17 years ago
Looking Ahead: The Pharmaceutical-Science Industryabout 17 years ago
Statistical Solutions: Square Root of (N) + 1 Sampling Planabout 17 years ago
Formulation and Evaluation of Famotidine Floating Matrix Tabletsabout 17 years ago
Report From: Indiaabout 17 years ago
The Emerging Markets of the Eastabout 17 years ago
New Leadership Seeks to Transform FDAabout 17 years ago
Quality by Design for Generic Drugsabout 17 years ago
Getting the Truth out of Dissolution Testingabout 17 years ago
Technical Note: The Case for Supplier QualificationAdvertisement
Related to this article
Mahmood Majeed, ZS, explains why measurable AI outcomes in pharma supply chain and manufacturing jumped from 29% to 53%, and how GMP limits and GxP validation shape adoption.
BMS-Tempus, Roche-Zymeworks, and LGM-Sannova deals show what AI data, trispecifics, and nitrosamine testing mean for CMC, QA, and development teams.
Univar Solutions scientists developed a lidocaine cream built on starch, sorbitol, coconut oil, and beeswax that matched a commercial benchmark on viscosity, assay, and hydration.
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.
FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Nitrosamine Problems and Industry Solutions: PharmTech Explained
2
AAPS PharmSci 360 2026: E&L Standards Harmonization
3
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
4
Ask the Expert: Choosing Ingredient Suppliers
5